In the MIROCALS trial, Gilbert Bensimon and colleagues1 showed that low-dose interleukin-2 (IL-2) added to riluzole did not significantly reduce mortality in an unadjusted analysis of patients with ...
We thank Yutaka Shimazu for his insightful comments. We agree that our positive findings1–4 highlight the urgent need for further work on biomarkers of neuronal damage and immune mechanisms in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback